Oroten HCT Tablets 10/40/12.5 mg
Amlodipine Besylate · Olmesartan Medoxomil +1 more
Prescription medication · Combination
Korea Pharmaceutical Co., Ltd.
MFDS item code 201805365 · Approved 2018.12.28
This product's status changed to Approval withdrawn on 2023.06.21. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with amlodipine and olmesartan combination therapy
The combination therapy of amlodipine and olmesartan medoxomil is used when it is difficult to control blood pressure in patients with essential hypertension. This medication helps lower blood pressure by dilating blood vessels and reduces the burden on the cardiovascular system. It effectively aids in managing blood pressure even when it is not adequately controlled. This contributes to preventing complications associated with hypertension. Therefore, it is useful in the treatment of essential hypertension.
Take 1 tablet of this drug once daily with water, with or without food. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before administering this drug, it is recommended that the doses of the individual components (amlodipine and olmesartan medoxomil, as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this drug may be considered as follows. The maximum dose of this drug is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this drug 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this drug 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this drug 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this drug 5/40/25mg or this drug 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The amounts of each component are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg ※ Patients with renal impairment The maximum dose of this drug for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This drug must not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). ※ Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment. The maximum dose of this drug for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This drug must not be administered to patients with severe hepatic impairment. ※ Elderly patients (65 years and older) In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. Because experience with this drug in elderly patients over 75 years of age is very limited, monitor very carefully when administering this drug.
Safety and efficacy in pediatric patients under 18 years of age have not been established; administration of this drug is not recommended.
This medication may cause serious harm or death to the fetus and newborn during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. It should not be used by individuals with hypersensitivity to this drug, its ingredients, or similar medications, nor by pregnant or breastfeeding women, patients with severe hypotension, and those with severe heart, kidney, or liver diseases. Patients with reduced blood volume or impaired kidney function may experience hypotensive symptoms during the initial use of this medication, so their condition should be closely monitored before and during treatment. This drug may affect kidney function, so patients with reduced kidney function should regularly check potassium, creatinine, and uric acid levels through blood tests. Patients with liver disease or impaired liver function should be cautious as hepatic coma may occur with this medication, and it is not recommended for patients with severe liver disease. As this medication lowers blood pressure, it may cause dizziness or lightheadedness; therefore, caution is advised when driving or operating hazardous machinery. This drug may cause skin sensitivity to sunlight, so exposure to sunlight should be avoided, or appropriate ultraviolet protection measures should be taken while using it. There may be interactions with other medications during use, particularly with lithium, nonsteroidal anti-inflammatory drugs, and other antihypertensives, so consultation with a specialist is necessary. In case of overdose, severe hypotension, palpitations, electrolyte imbalances, etc., may occur, and immediate medical attention should be sought if symptoms appear. This medication is not recommended for children as its safety and efficacy have not been established, and elderly patients should start at a low dose considering potential decreases in liver and kidney function. During breastfeeding, the components of this drug may be passed into breast milk affecting the baby, so cessation of breastfeeding or avoidance of this drug is recommended. When storing this medication, keep it out of reach of children and store it in a cool, dry place away from heat and direct sunlight.
Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, appetite loss, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, sensitivity to stimulation, anxiety, mood changes, sleep disturbances, orthostatic dizziness, syncope, taste disorders, hypertonia, sensory loss, dysesthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremors, visual disturbances, decreased tears, worsening myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina pectoris, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, bloating, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, skin lupus erythematosus-like reaction, eruption-like pustulosis, exfoliative dermatitis, hyperhidrosis, photosensitivity, itching, purpura, Quincke's edema, rash, recurrence of skin lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle cramps, joint swelling, muscle weakness, ankle swelling, arthralgia, arthritis, low back pain, hyporeflexia, myalgia, bone pain, frequent urination, acute renal failure, hematuria, urinary disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial swelling, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, increased gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption, drug hypersensitivity, epigastric pain, decreased libido, abdominal edema, lethargy, altered consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, acute respiratory distress syndrome
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight container to protect it from air and moisture and kept at a cool room temperature between 1 to 30 degrees Celsius.
Round film-coated tablet in grayish-red
28 tablets (14 tablets/PTP×2) / carton
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate · Olmesartan Medoxomil +1 more
Prescription medication · Combination
Korea Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg +1 more
Tablet · Prescription medication · Combination
Daicel Corporation (Co., Ltd.)
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
HanKook Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg +1 more
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.